Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De Sells 79,712 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 79,712 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the sale, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This trade represents a 9.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Vir Biotechnology Stock Performance

Shares of NASDAQ:VIR opened at $5.58 on Friday. Vir Biotechnology, Inc. has a 52 week low of $5.49 and a 52 week high of $14.45. The company has a market cap of $765.26 million, a PE ratio of -1.42 and a beta of 1.14. The firm has a 50 day simple moving average of $8.36 and a 200 day simple moving average of $8.29.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. On average, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Hedge Funds Weigh In On Vir Biotechnology

A number of large investors have recently made changes to their positions in VIR. Intech Investment Management LLC acquired a new position in Vir Biotechnology in the 3rd quarter valued at approximately $191,000. Charles Schwab Investment Management Inc. increased its stake in shares of Vir Biotechnology by 13.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock worth $8,496,000 after acquiring an additional 136,087 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Vir Biotechnology during the third quarter worth $138,000. Public Sector Pension Investment Board boosted its position in Vir Biotechnology by 1.4% during the third quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock valued at $1,455,000 after purchasing an additional 2,600 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in Vir Biotechnology in the third quarter valued at about $118,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on VIR shares. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research report on Thursday, February 27th. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. Leerink Partners boosted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Barclays raised their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.67.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).